Clinical Trial: Acalabrutinib in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL

Brief Summary: To evaluate the safety and preliminary efficacy of acalabrutinib in combination with obinutuzumab in 2 separate cohorts of patients.

Detailed Summary:
Sponsor: Acerta Pharma BV

Current Primary Outcome: The overall response rate (ORR) at 12 months with the combination of acalabrutinib + obinutuzumab in patients [ Time Frame: 12 Months ]

Original Primary Outcome: The overall response rate (ORR) at 12 months with the combination of ACP-196 + obinutuzumab in patients [ Time Frame: 12 Months ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Acerta Pharma BV

Dates:
Date Received: November 19, 2014
Date Started: November 2014
Date Completion:
Last Updated: December 2, 2016
Last Verified: December 2016